Clinical Report: Case Study of Type B Insulin Resistance with Glycemic Variability
Overview
This report details a rare case of Type B insulin resistance (TBIR) in a 20-year-old Hispanic woman presenting with diabetic ketoacidosis and extreme insulin resistance. The case highlights the importance of early diagnosis and the use of immunosuppressive therapy in managing TBIR.
Background
Type B insulin resistance is a rare autoimmune disorder characterized by the presence of autoantibodies against the insulin receptor, leading to severe insulin resistance and glycemic variability. It predominantly affects middle-aged women but can occur in younger individuals and across various ethnicities. Understanding TBIR is crucial for timely intervention and management to prevent severe metabolic complications.
Data Highlights
Case details include: a 20-year-old Hispanic woman with diabetic ketoacidosis, severe hyperglycemia requiring over 5,000 units of insulin daily, and subsequent reduction to 200 units with adjunctive therapy.
Key Findings
TBIR is caused by IgG autoantibodies that can act as partial agonists, leading to both hyperglycemia and hypoglycemia.
Patients often present with refractory hyperglycemia despite high insulin doses, cachexia, and acanthosis nigricans.
Continuous glucose monitoring is essential for managing glycemic fluctuations in TBIR patients.
Immunosuppressive therapy, including rituximab and azathioprine, can lead to remission and discontinuation of insulin therapy.
This case is the first to report the use of a GLP-1 receptor agonist (semaglutide) in TBIR to reduce insulin requirements.
Clinical Implications
Early recognition of TBIR is vital for effective management, particularly in young patients presenting with severe insulin resistance. Clinicians should consider individualized immunosuppressive regimens and utilize continuous glucose monitoring to optimize treatment outcomes and prevent severe hypoglycemia.
Conclusion
This case underscores the complexity of TBIR and the importance of a structured approach to diagnosis and management. Vigilant metabolic monitoring and timely immunosuppressive therapy are critical for improving patient outcomes.
